3320 — China Resources Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapContrarian

Market Cap
HK$29.78bn
Enterprise Value
HK$158.86bn
Revenue
CNY257.67bn

Annual income statement for China Resources Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	fx Final	fx Final	Final	Final	Final
Revenue
Total Revenue	178,300	196,534	218,183	244,704	257,673
Cost of Revenue
Gross Profit	28,729	29,363	33,619	38,337	40,689
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	169,985	188,143	208,422	233,442	245,511
Operating Profit	8,315	8,391	9,761	11,262	12,163
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	6,294	6,978	8,361	9,880	10,930
Provision for Income Taxes
Net Income After Taxes	4,736	5,517	6,658	7,775	8,403
Minority Interest
Net Income Before Extraordinary Items
Net Income	2,933	3,128	3,500	3,854	3,351
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2,933	3,128	3,500	3,854	3,351
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.54	0.527	0.567	0.716	0.644
Dividends per Share